S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:TLSA

Tiziana Life Sciences - TLSA Stock Forecast, Price & News

$0.65
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.60
▼
$0.65
50-Day Range
$0.56
▼
$0.67
52-Week Range
$0.53
▼
$1.38
Volume
45,286 shs
Average Volume
47,671 shs
Market Capitalization
$66.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Tiziana Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
518.0% Upside
$4.00 Price Target
Short Interest
Healthy
0.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Tiziana Life Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.37) to ($0.32) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

621st out of 1,055 stocks

Pharmaceutical Preparations Industry

314th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

TLSA stock logo

About Tiziana Life Sciences (NASDAQ:TLSA) Stock

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.

Receive TLSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TLSA Stock News Headlines

January 21, 2023 | americanbankingnews.com
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update
January 4, 2023 | proactiveinvestors.com
Tiziana Life Sciences says IND filed for Phase 2 study of milciclib in combination with gemcitabine for non-small cell lung cancer
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 4, 2023 | finance.yahoo.com
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
January 3, 2023 | finance.yahoo.com
Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis
January 3, 2023 | proactiveinvestors.com
Tiziana Life Sciences hails more improvements in MS patient after 11 months dosing with intranasal foralumab
January 3, 2023 | tmcnet.com
Tiziana Life Sciences Announces Additional Clinical Improvements in
January 3, 2023 | finance.yahoo.com
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
December 29, 2022 | finance.yahoo.com
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
December 28, 2022 | proactiveinvestors.com
Tiziana Life Sciences ups R&D spend in first half of 2022 as it advances its next-generation therapeutics
December 27, 2022 | finance.yahoo.com
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
December 16, 2022 | finanznachrichten.de
Tiziana Life Sciences Ltd.: Tiziana to Participate in January Investor Meetings
December 16, 2022 | finance.yahoo.com
Tiziana to Participate in January Investor Meetings
December 15, 2022 | finanznachrichten.de
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
December 15, 2022 | proactiveinvestors.com
Tiziana Life Sciences reveals successful completion of intranasal foralumab pre-clinical safety study
December 15, 2022 | finance.yahoo.com
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
December 14, 2022 | finance.yahoo.com
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
December 6, 2022 | finance.yahoo.com
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
December 5, 2022 | finance.yahoo.com
TLSA: November’s Investor Day
November 23, 2022 | finance.yahoo.com
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
November 10, 2022 | finance.yahoo.com
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
November 4, 2022 | proactiveinvestors.com
Tiziana Life Sciences under the eye of Proactive research analyst John Savin
November 4, 2022 | finance.yahoo.com
Tiziana Life Sciences to Host Investor Call
November 2, 2022 | proactiveinvestors.com
Tiziana finishes enrolling first patient cohort for expanded access program evaluating Foralumab in advanced stage multiple sclerosis
November 2, 2022 | finance.yahoo.com
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
October 27, 2022 | proactiveinvestors.com
Tiziana Life Sciences starts enrollment of first patient cohort in... Tiziana Life Sciences starts enrollment of first patient cohort in...
See More Headlines
Receive TLSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TLSA Company Calendar

Today
1/28/2023
Next Earnings (Estimated)
5/19/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TLSA
CUSIP
N/A
CIK
1723069
Web
www.tizianalifesciences.com
Phone
44-20-7495-2379
Fax
N/A
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+518.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.12
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.40 per share
Price / Book
1.62

Miscellaneous

Outstanding Shares
102,270,000
Free Float
61,548,000
Market Cap
$66.20 million
Optionable
Not Optionable
Beta
0.82

Key Executives

  • Mr. Gabriele Marco Antonio Cerrone M.B.A. (Age 50)
    MBA, Founder, Exec. Chairman & Interim CEO
    Comp: $1.19M
  • Dr. Andrea Brancale
    Scientific Founder
  • Mr. Richard Clarkson Ph.D.
    Scientific Founder
  • Mr. Andrew Westwell Ph.D.
    Scientific Founder
  • Ms. Keeren Shah (Age 45)
    Chief Financial Officer
  • Dr. Matthew W. Davis M.D.
    RPh, Chief Medical Officer & Acting Chief Scientific Officer
  • Prof. Napoleone Ferrara M.D. (Age 65)
    Member of Scientific Advisory Board
  • Prof. Roberto Pellicciari Ph.D.
    Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













TLSA Stock - Frequently Asked Questions

Should I buy or sell Tiziana Life Sciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tiziana Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TLSA shares.
View TLSA analyst ratings or view top-rated stocks.

What is Tiziana Life Sciences' stock price forecast for 2023?

1 Wall Street analysts have issued 12-month price targets for Tiziana Life Sciences' stock. Their TLSA share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 518.0% from the stock's current price.
View analysts price targets for TLSA or view top-rated stocks among Wall Street analysts.

How have TLSA shares performed in 2023?

Tiziana Life Sciences' stock was trading at $0.5985 on January 1st, 2023. Since then, TLSA stock has increased by 8.2% and is now trading at $0.6473.
View the best growth stocks for 2023 here.

Are investors shorting Tiziana Life Sciences?

Tiziana Life Sciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 65,400 shares, an increase of 15.5% from the December 31st total of 56,600 shares. Based on an average daily volume of 53,300 shares, the short-interest ratio is currently 1.2 days.
View Tiziana Life Sciences' Short Interest.

When is Tiziana Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 19th 2023.
View our TLSA earnings forecast.

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Pfizer (PFE), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Moderna (MRNA), Enterprise Products Partners (EPD), Novavax (NVAX), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Tiziana Life Sciences IPO?

(TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the NASDAQ under the ticker symbol "TLSA."

How do I buy shares of Tiziana Life Sciences?

Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tiziana Life Sciences' stock price today?

One share of TLSA stock can currently be purchased for approximately $0.65.

How much money does Tiziana Life Sciences make?

Tiziana Life Sciences (NASDAQ:TLSA) has a market capitalization of $66.20 million.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The official website for the company is www.tizianalifesciences.com. The company can be reached via phone at 44-20-7495-2379 or via email at info@tizianalifesciences.com.

This page (NASDAQ:TLSA) was last updated on 1/28/2023 by MarketBeat.com Staff